The tumor cells and THP‐1 cells co‐culture assay demonstrated that TZ‐dSA3‐12 robustly activates the STING pathway in the tumor microenvironment through HER2‐dependent targeting and FcγR‐mediated innate immune activation. The gene discussed is FCGR2A; the disease is neoplasm.